MedTrace Logo

A Study to Assess the Safety and Efficacy of Vilaprisan in Japanese Subjects With Uterine Fibroids and Heavy Menstrual Bleeding

NCT03476928 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 153

Last updated 2022-07-08

No results posted yet for this study

Summary

To evaluate the safety and efficacy of vilaprisan in Japanese subjects with uterine fibroids and heavy menstrual bleeding (HMB).

Conditions

  • Uterine Fibroids and Heavy Menstrual Bleeding

Interventions

DRUG

Vilaprisan (BAY1002670)

2mg, once daily, oral

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-30
Primary Completion
2021-07-12
Completion
2021-07-12

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03476928 on ClinicalTrials.gov